IP Library › Granted Patent US 12,595,510
Granted Patent B2
US 12,595,510 · App. 17/292,926 · Granted Apr 7, 2026

Methods and compositions for prediction of response to a therapy of an inflammatory bowel disease

Inventors: Frederic Baribaud (Broomall, PA); Carrie Brodmerkel (West Chester, PA); Xilin Li (Wallingford, PA); Takahiro Sato (Philadelphia, PA); Shannon Telesco (Lansdale, PA); Feifei Yang (Wayne, PA); Prerak Desai (Lansdale, PA)
Assignee: JANSSEN BIOTECH, INC.
C12Q1/6883C12Q2600/106C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,595,510
App. No.
17/292,926
Granted
Apr 7, 2026
Kind
B2
Abstract

Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and kits for predicting the response to the therapy of the inflammatory bowel disease.

Claims (24)

1 . A method of treating a subject diagnosed with an inflammatory bowel disease (IBD), comprising:

(i) identifying a subject diagnosed with an IBD to be a responder to an IBD treatment comprising an anti-interleukin 23 (anti-IL23) antibody, the method comprising:

a). contacting a sample from a subject with a set of probes capable of detecting a panel of biomarkers comprising 13 biomarkers selected from the group consisting of CKLF-like MARVEL transmembrane domain containing 2 (CMTM2), complement C5a receptor 1 (C5AR1), fibroblast growth factor 2 (FGF2), glycerol kinase (GK), hepatocyte growth factor (HGF), interleukin 1 receptor antagonist (IL1RN), leukocyte immunoglobulin like receptor A2 (LILRA2), nicotinamide phosphoribosyltransferase (NAMPT), pappalysin 1 (PAPPA), synuclein alpha (SNCA), superoxide dismutase 2, mitochondrial (SOD2), STEAP4 metalloreductase (STEAP4), and zinc finger BED-type containing 3 (ZBED3);

b). determining a signature score of the panel of biomarkers, wherein the determining comprises determining the baseline gene expression levels of the panel of biomarkers; and

c). identifying a subject to be a responder to the IBD treatment if the signature score of the panel of biomarkers is above a pre-specified threshold indicative of response; and

(ii) administering to the subject who has been identified as a responder in c) a therapeutically effective amount of the IBD treatment.

2 . The method of claim 1 , wherein

a. the sample is obtained before the subject is treated with the IBD treatment; or

b. the probe is selected from the group consisting of an aptamer, an antibody, an affibody, a peptide, and a nucleic acid.

3 . The method of claim 2 , wherein the probe is a nucleic acid.

4 . The method of claim 2 , wherein the probe is selected from the group consisting of SEQ ID NOS. 1-14, SEQ ID NO. 17, SEQ ID NO. 20, SEQ ID NO. 23, SEQ ID NO. 26, SEQ ID NO. 29, SEQ ID NO. 32, SEQ ID NO. 35, SEQ ID NO. 38, SEQ ID NO. 41, SEQ ID NO. 44, SEQ ID NO. 47, and SEQ ID NO. 50.

5 . The method of claim 1 , wherein the gene expression levels of the panel of biomarkers are determined by quantitative polymerase chain reaction (qPCR).

6 . The method of claim 5 , wherein the qPCR primers are selected from the group consisting of SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO. 19, SEQ ID NO. 21, SEQ ID NO. 22, SEQ ID NO. 24, SEQ ID NO. 25, SEQ ID NO. 27, SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 31, SEQ ID NO. 33, SEQ ID NO. 34, SEQ ID NO. 36, SEQ ID NO. 37, SEQ ID NO. 39, SEQ ID NO. 40, SEQ ID NO. 42, SEQ ID NO. 43, SEQ ID NO. 45, SEQ ID NO. 46, SEQ ID NO. 48, SEQ ID NO. 49, SEQ ID NO. 51, and SEQ ID NO. 52.

7 . The method of claim 1 , wherein the pre-specified threshold level is

a. selected from the group consisting of between-3.9000 and 1.1000;

b. −3.8234; or

c. 1.0000.

8 . The method of claim 1 , further comprising predicting the response by one or more other characteristics of the subject.

9 . The method of claim 8 , wherein the other characteristics are selected from the group consisting of protein levels, gut microbiome, histology and clinical characteristics of the subject.

10 . The method of claim 1 , further comprising measuring the response at or after week 6, 30 or 50 of the IBD treatment, or anytime in between.

11 . The method of claim 1 , wherein the sample is a tissue sample or a blood sample.

12 . The method of claim 1 , wherein the IBD is at least one of ulcerative colitis (UC) or Crohn's disease (CD).

13 . The method of claim 1 , wherein the subject had previously failed or were intolerant of at least one therapy selected from the group consisting of: vedolizumab, corticosteroids, azathioprine (AZA), and 6 mercaptopurine (6 MP), or the subject had demonstrated corticosteroid dependence.

14 . The method of claim 1 , wherein the anti-IL23 antibody is ustekinumab.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2025
From: BARIBAUD, FREDERIC; BRODMERKEL, CARRIE; LI, XILIN; SATO, TAKAHIRO; TELESCO, SHANNON; DESAI, PRERAK
To: JANSSEN RESEARCH & DEVELOPMENT, LLC
Reel/Frame 072329/0168 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2025
From: YANG, FEIFEI
To: JANSSEN GLOBAL SERVICES, LLC
Reel/Frame 072329/0227 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2025
From: JANSSEN RESEARCH & DEVELOPMENT, LLC
To: JANSSEN BIOTECH, INC.
Reel/Frame 072329/0234 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2025
From: JANSSEN GLOBAL SERVICES, LLC
To: JANSSEN BIOTECH, INC.
Reel/Frame 072329/0273 →
Continuity (2)
Provisional Application 62767636 · Nov 15, 2018
Related Publication 20220002805A1 · Jan 6, 2022
References Cited (44)
US 5739282A · Colotta · 1998 [cited by examiner]
US 20050272080A1 · Palma et al. · 2005 [cited by applicant]
US 20070157325A1 · Mojtahedian · 2007 [cited by applicant]
US 20090054253A1 · Li et al. · 2009 [cited by applicant]
US 20100069256A1 · Baribaud et al. · 2010 [cited by applicant]
US 20150010544A1 · Ariaans et al. · 2015 [cited by applicant]
US 20160304969A1 · Ayers et al. · 2016 [cited by applicant]
US 20170145044A1 · Hudson et al. · 2017 [cited by applicant]
JP 2012501452A · 2012 [cited by applicant]
JP 2019501133A · 2019 [cited by applicant]
JP 2020501699A · 2020 [cited by applicant]
WO WO2010025340A2 · 2010 [cited by applicant]
WO WO2010062663 · 2010 [cited by examiner]
WO WO2017091544A1 · 2017 [cited by applicant]
WO WO2018112232A1 · 2018 [cited by applicant]
Kuboyama, Kurume Med J 45:33-37, 1998. [cited by examiner]
Wils et al, Clin Gastroenterol Hepatol 14:242-250, epub 2015. [cited by examiner]
Arijs et al., 2009, “Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis,” Gut, 58(12):1612-1619. [cited by applicant]
Callahan et al., 2016, “DADA2: High-resolution sample inference from Illumina amplicon data,” Nat. Methods, 13(7):581-583 and Online Methods (7 pages). [cited by applicant]
ClinicalTrials.gov No. NCT01863771, “A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis,” first posted: May 29, 2013, last updated: Apr. 5, 2017 (9 p… [cited by applicant]
ClinicalTrials.gov No. NCT01988961, “A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active… [cited by applicant]
Ferrante et al., 2007, “Predictors of early response to infliximab in patients with ulcerative colitis,” Inflamm. Bowel Dis., 13(2):123-128. [cited by applicant]
Hajian-Tilaki, 2013, “Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation,” Caspian J. Intern. Med., 4(2):627-635. [cited by applicant]
Hanley et al., 1982, “The meaning and use of the area under a receiver operating characteristic (ROC) curve,” Radiology, 143(1):29-36. [cited by applicant]
Hanzelmann et al., 2013, “GSVA: gene set variation analysis for microarray and RNA-seq data,” BMC Bioinformatics, 14:7 (15 pages). [cited by applicant]
Hibi et al., 2017, “Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study—(P… [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2019/061459 (Pub No. WO 2020102519) mailed Feb. 11, 2020 (19 pages). [cited by applicant]
Irizarry et al., 2003, “Exploration, normalization, and summaries of high density oligonucleotide array probe level data,” Biostatistics, 4(2):249-264. [cited by applicant]
Kolho et al., 2015, “Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation,” Am. J. Gastroenterol., 110(6):921-930 and Supplemental Materials (13 pages). [cited by applicant]
Kozich et al., 2013, “Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform,” Appl. Environ. Microbiol., 79(17):5112-5120. [cited by applicant]
Lewis et al., 1997, “Stool form scale as a useful guide to intestinal transit time,” Scand J. Gastroenterol., 32(9):920-924. [cited by applicant]
Li et al., 2018, “Molecular Comparison of Adult and Pediatric Ulcerative Colitis Indicates Broad Similarity of Molecular Pathways in Disease Tissue,” J. Pediatr. Gastroenterol. Nutr., 67(1):45-52. [cited by applicant]
Liberzon et al., 2015, “The Molecular Signatures Database (MSigDB) hallmark gene set collection,” Cell Syst., 1(6):417-425 and Supplemental Information (20 pages). [cited by applicant]
Love et al., 2014, “Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2,” Genome Biol., 15(12):550 (21 pages). [cited by applicant]
McMurdie eta 1., 2013, “phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data,” PLoS One, 8(4):e61217 (11 pages). [cited by applicant]
Ritchie et al., 2015, “Iimma powers differential expression analyses for RNA-sequencing and microarray studies,” Nucleic Acids Res., 43(7):e47 (13 pages). [cited by applicant]
Rutgeerts et al., 2009, “Biological therapies for inflammatory bowel diseases,” Gastroenterology, 136(4):1182-1197. [cited by applicant]
Sandborn et al., 2014, “Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis,” Gastroenterology, 146(1):85-95; quiz e14-5 and Supplemental Materials (Epub… [cited by applicant]
Shaw et al., 2016, “Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease,” Genome Med., 8(1):75 (13 pages). [cited by applicant]
Telesco et al., 2018, “Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis,” Gastroenterology, 155(4):1008-1011.e8 (12 pages). [cited by applicant]
Travis et al., 2012, “Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS),” Gut, 61(4):535-542 (Epub 2011). [cited by applicant]
Wang et al., 2007, “Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy,” Appl. Environ. Microbiol., 73(16):5261-5267. [cited by applicant]
West et al., 2017, “Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease,” Nat. Med., 23(5):579-589 and Online Metho… [cited by applicant]
Zhou et al., 2018, “Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction,” mSystems, 3(1):e00188-17 (14 pages). [cited by applicant]